Chimeric Antigen Receptor T Cells therapy (Institute Of Hematology & Blood Diseases Hospital)

N/A

Report date: 2025/07/07 20:00:09

Base Information

Drug NameChimeric Antigen Receptor T Cells therapy (Institute Of Hematology & Blood Diseases Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInstitute Of Hematology & Blood Diseases Hospital
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Hematology & Blood Diseases Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A